Gongwin Biopharm Holdings Co (ROCO:6617) Total Liabilities: NT$279.20 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6617 Gongwin Biopharm Holdings Co Ltd ROCO:6617
70 GF Score
Price NT$103.00
GF Value NT$151.75
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Gongwin Biopharm Holdings Co Total Liabilities?

Gongwin Biopharm Holdings Co ROCO:6617 +3.00% 70 Total Liabilities is NT$279.20 Mil as of Dec. 2025. GuruFocus rates ROCO:6617 with a GF Score™ of 70/100 and a GF Value™ of NT$151.75 (Significantly Undervalued). The stock has 6 warning signs investors should review.

Gongwin Biopharm Holdings Co's Total Liabilities for the quarter that ended in Dec. 2025 was NT$279.20 Mil.

Gongwin Biopharm Holdings Co's quarterly Total Liabilities increased from Jun. 2025 (NT$234.29 Mil) to Sep. 2025 (NT$260.15 Mil) and increased from Sep. 2025 (NT$260.15 Mil) to Dec. 2025 (NT$279.20 Mil).

Gongwin Biopharm Holdings Co's annual Total Liabilities increased from Dec. 2023 (NT$203.53 Mil) to Dec. 2024 (NT$281.84 Mil) but then declined from Dec. 2024 (NT$281.84 Mil) to Dec. 2025 (NT$279.20 Mil).

Gongwin Biopharm Holdings Co Total Liabilities Historical Data

* Premium members only.

The historical data trend for Gongwin Biopharm Holdings Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gongwin Biopharm Holdings Co Total Liabilities Chart

Gongwin Biopharm Holdings Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 184.43 248.70 203.53 281.84 279.20

Gongwin Biopharm Holdings Co Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 281.84 254.38 234.29 260.15 279.20
ROCO:6617
70GF Score
Gongwin Biopharm Holdings Co Ltd ROCO:6617
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gongwin Biopharm Holdings Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Gongwin Biopharm Holdings Co's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=180.416+(9.25+89.531
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=279.20

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=2797.024-2517.827
=279.20

Gongwin Biopharm Holdings Co's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=180.416+(9.25+89.531
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=279.20

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=2797.024-2517.827
=279.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of NT$279.20 Mil mean?
Gongwin Biopharm Holdings Co (ROCO:6617) has a Total Liabilities of NT$279.20 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Gongwin Biopharm Holdings Co and its competitors.
Is Gongwin Biopharm Holdings Co's Total Liabilities too high?
Gongwin Biopharm Holdings Co's current Total Liabilities is NT$279.20 Mil. Overall, Gongwin Biopharm Holdings Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gongwin Biopharm Holdings Co's Total Liabilities compare to VRTX and REGN?
Gongwin Biopharm Holdings Co's Total Liabilities of NT$279.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Gongwin Biopharm Holdings Co and its competitors. Gongwin Biopharm Holdings Co's current Total Liabilities is NT$279.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gongwin Biopharm Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Gongwin Biopharm Holdings Co (ROCO:6617) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$151.75, compared to a current price of NT$103.00 — trading 32.1% below its estimated fair value. The current Total Liabilities is NT$279.20 Mil. Gongwin Biopharm Holdings Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Gongwin Biopharm Holdings Co (ROCO:6617), the current Total Liabilities is NT$279.20 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gongwin Biopharm Holdings Co (ROCO:6617) Overvalued in 2026?

Based on GuruFocus' analysis, Gongwin Biopharm Holdings Co stock appears to be undervalued. The current stock price of NT$103.00 is trading 32.1% below its estimated GF Value™ of NT$151.75. GuruFocus considers Gongwin Biopharm Holdings Co to be Significantly Undervalued.

Key valuation signals for ROCO:6617:

  • Total Liabilities: NT$279.20 Mil
  • GF Value™: NT$151.75 vs. price of NT$103.00 (32.1% below fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the ROCO:6617 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gongwin Biopharm Holdings Co Business Description

Address 3rd Floor, No.80, Jianguo North Road, Section 1, Zongshan District, Taipei, TWN, 10491
Gongwin Biopharm Holdings Co Ltd is a Taiwan-based biopharmaceutical company focused on developing novel anti-cancer drugs. The company develops products related to central lung serious tracheal obstruction, primary liver cancer, malignant pleural effusion, and tracheal adenoid cystic carcinoma. The Group includes pharmaceutical research and development, drug testing, pharmaceutical technology consulting, biotechnology services, technology transfer, and the sale of new drugs.
70GF Score

Get the complete analysis for ROCO:6617

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$103.00
Price
NT$151.75
GF Value